# Lyell Immunopharma, Inc.: financial statements, quarterly

LYEL · Nasdaq · CIK 1806952 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lyel.md) · [Financials](/companies/lyel/financials.md) · [Filings](/companies/lyel/filings.md) · [Insiders](/companies/lyel/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lyel/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001628280-24-046285.md) | [0.0 d](/filings/0001628280-26-017253.md) | [0.0](/filings/0001628280-25-025135.md) | [0.0](/filings/0001806952-25-000008.md) | [0.0](/filings/0001628280-25-051619.md) | [0.0 d](/filings/0001628280-26-017253.md) | [0.0](/filings/0001628280-26-031284.md) | [0.0](/filings/0001628280-26-054367.md) | [0.0](/filings/0001628280-25-051619.md) | [0.0 d](/filings/0001628280-26-017253.md) | [0.0](/filings/0001628280-26-031284.md) | [0.0](/filings/0001628280-26-054367.md) |
| Research and development | $m | [43.8](/filings/0001628280-24-046285.md) | [47.0 d](/filings/0001628280-24-007592.md) | [43.2](/filings/0001628280-25-025135.md) | [40.3](/filings/0001806952-25-000008.md) | [39.5](/filings/0001628280-25-051619.md) | not reported | [43.4](/filings/0001628280-26-031284.md) | [34.9](/filings/0001628280-26-054367.md) | [28.2](/filings/0001628280-25-051619.md) | not reported | [36.6](/filings/0001628280-26-031284.md) | [39.5](/filings/0001628280-26-054367.md) |
| Operating income | $m | [(59.0)](/filings/0001628280-24-046285.md) | [(59.5) d](/filings/0001628280-26-017253.md) | [(55.6)](/filings/0001628280-25-025135.md) | [(51.5)](/filings/0001806952-25-000008.md) | [(50.5)](/filings/0001628280-25-051619.md) | [(201) d](/filings/0001628280-26-017253.md) | [(57.4)](/filings/0001628280-26-031284.md) | [(47.1)](/filings/0001628280-26-054367.md) | [(37.3)](/filings/0001628280-25-051619.md) | [(128) d](/filings/0001628280-26-017253.md) | [(44.3)](/filings/0001628280-26-031284.md) | [(47.3)](/filings/0001628280-26-054367.md) |
| Net income | $m | [(50.9)](/filings/0001628280-24-046285.md) | [(52.9) d](/filings/0001628280-26-017253.md) | [(60.7)](/filings/0001628280-25-025135.md) | [(45.8)](/filings/0001806952-25-000008.md) | [(44.6)](/filings/0001628280-25-051619.md) | [(192) d](/filings/0001628280-26-017253.md) | [(52.2)](/filings/0001628280-26-031284.md) | [(42.7)](/filings/0001628280-26-054367.md) | [(38.8)](/filings/0001628280-25-051619.md) | [(141) d](/filings/0001628280-26-017253.md) | [(24.2)](/filings/0001628280-26-031284.md) | [(44.8)](/filings/0001628280-26-054367.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001628280-24-046285.md) | not reported | [(0.24)](/filings/0001628280-25-025135.md) | [(3.59)](/filings/0001806952-25-000008.md) | [(3.48)](/filings/0001628280-25-051619.md) | not reported | [(3.54)](/filings/0001628280-26-031284.md) | [(2.89)](/filings/0001628280-26-054367.md) | [(2.13)](/filings/0001628280-25-051619.md) | not reported | [(1.10)](/filings/0001628280-26-031284.md) | [(1.92)](/filings/0001628280-26-054367.md) |
| Basic EPS | $ per share | [(0.20)](/filings/0001628280-24-046285.md) | not reported | [(0.24)](/filings/0001628280-25-025135.md) | [(3.59)](/filings/0001806952-25-000008.md) | [(3.48)](/filings/0001628280-25-051619.md) | not reported | [(3.54)](/filings/0001628280-26-031284.md) | [(2.89)](/filings/0001628280-26-054367.md) | [(2.13)](/filings/0001628280-25-051619.md) | not reported | [(1.10)](/filings/0001628280-26-031284.md) | [(1.92)](/filings/0001628280-26-054367.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [286](/filings/0001628280-24-046285.md) | [146](/filings/0001628280-26-017253.md) | [126](/filings/0001628280-25-025135.md) | [133](/filings/0001806952-25-000008.md) | [100](/filings/0001628280-25-051619.md) | [106](/filings/0001628280-26-017253.md) | [120](/filings/0001628280-26-031284.md) | [98.8](/filings/0001628280-26-054367.md) | [124](/filings/0001628280-25-051619.md) | [60.2](/filings/0001628280-26-054367.md) | [90.8](/filings/0001628280-26-031284.md) | [73.0](/filings/0001628280-26-054367.md) |
| Current assets | $m | [587](/filings/0001628280-23-037360.md) | [555](/filings/0001628280-25-011978.md) | [534](/filings/0001628280-24-020467.md) | [500](/filings/0001628280-24-035617.md) | [450](/filings/0001628280-24-046285.md) | [380](/filings/0001628280-26-017253.md) | [309](/filings/0001628280-25-025135.md) | [282](/filings/0001806952-25-000008.md) | [328](/filings/0001628280-25-051619.md) | [261](/filings/0001628280-26-054367.md) | [267](/filings/0001628280-26-031284.md) | [214](/filings/0001628280-26-054367.md) |
| Total assets | $m | [795](/filings/0001628280-23-037360.md) | [750](/filings/0001628280-25-011978.md) | [694](/filings/0001628280-24-020467.md) | [654](/filings/0001628280-24-035617.md) | [619](/filings/0001628280-24-046285.md) | [491](/filings/0001628280-26-017253.md) | [430](/filings/0001628280-25-025135.md) | [385](/filings/0001806952-25-000008.md) | [408](/filings/0001628280-25-051619.md) | [340](/filings/0001628280-26-054367.md) | [351](/filings/0001628280-26-031284.md) | [311](/filings/0001628280-26-054367.md) |
| Current liabilities | $m | [35.1](/filings/0001628280-23-037360.md) | [34.5](/filings/0001628280-25-011978.md) | [32.4](/filings/0001628280-24-020467.md) | [30.9](/filings/0001628280-24-035617.md) | [33.5](/filings/0001628280-24-046285.md) | [53.8](/filings/0001628280-26-017253.md) | [41.3](/filings/0001628280-25-025135.md) | [36.9](/filings/0001806952-25-000008.md) | [31.9](/filings/0001628280-25-051619.md) | [49.4](/filings/0001628280-26-054367.md) | [36.9](/filings/0001628280-26-031284.md) | [39.9](/filings/0001628280-26-054367.md) |
| Total liabilities | $m | [97.4](/filings/0001628280-23-037360.md) | [95.1](/filings/0001628280-25-011978.md) | [91.1](/filings/0001628280-24-020467.md) | [87.6](/filings/0001628280-24-035617.md) | [88.5](/filings/0001628280-24-046285.md) | [108](/filings/0001628280-26-017253.md) | [93.3](/filings/0001628280-25-025135.md) | [86.5](/filings/0001806952-25-000008.md) | [78.8](/filings/0001628280-25-051619.md) | [91.9](/filings/0001628280-26-054367.md) | [77.0](/filings/0001628280-26-031284.md) | [77.3](/filings/0001628280-26-054367.md) |
| Shareholders' equity | $m | [698](/filings/0001628280-24-046285.md) | [655](/filings/0001628280-26-017253.md) | [603](/filings/0001806952-25-000008.md) | [567](/filings/0001628280-25-051619.md) | [531](/filings/0001628280-25-051619.md) | [383](/filings/0001628280-26-054367.md) | [337](/filings/0001628280-26-054367.md) | [299](/filings/0001628280-26-054367.md) | [329](/filings/0001628280-25-051619.md) | [248](/filings/0001628280-26-054367.md) | [274](/filings/0001628280-26-054367.md) | [234](/filings/0001628280-26-054367.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(37.7) d](/filings/0001628280-24-046285.md) | [(40.6) d](/filings/0001628280-26-017253.md) | [(42.0)](/filings/0001628280-25-025135.md) | [(38.1) d](/filings/0001806952-25-000008.md) | [(35.0) d](/filings/0001628280-25-051619.md) | [(47.2) d](/filings/0001628280-26-017253.md) | [(54.7)](/filings/0001628280-26-031284.md) | [(34.5) d](/filings/0001628280-26-054367.md) | [(28.6) d](/filings/0001628280-25-051619.md) | [(32.3) d](/filings/0001628280-26-017253.md) | [(38.5)](/filings/0001628280-26-031284.md) | [(33.9) d](/filings/0001628280-26-054367.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001628280-24-046285.md) | [0.0 d](/filings/0001628280-26-017253.md) | [0.0](/filings/0001628280-25-025135.md) | [0.3 d](/filings/0001806952-25-000008.md) | [0.1 d](/filings/0001628280-25-051619.md) | [0.0 d](/filings/0001628280-26-017253.md) | [0.2](/filings/0001628280-26-031284.md) | [0.2 d](/filings/0001628280-26-054367.md) | [0.1 d](/filings/0001628280-25-051619.md) | [0.3 d](/filings/0001628280-26-017253.md) | [0.1](/filings/0001628280-26-031284.md) | [0.3 d](/filings/0001628280-26-054367.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [248](/filings/0001628280-23-037360.md) | [250](/filings/0001628280-24-020467.md) | [250](/filings/0001628280-24-035617.md) | [251](/filings/0001628280-24-046285.md) | [254](/filings/0001628280-25-025135.md) | [12.8](/filings/0001806952-25-000008.md) | [12.8](/filings/0001628280-25-051619.md) | [14.8](/filings/0001628280-26-031284.md) | [14.8](/filings/0001628280-26-054367.md) | [18.3](/filings/0001628280-25-051619.md) | [21.9](/filings/0001628280-26-031284.md) | [23.4](/filings/0001628280-26-054367.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,505,141 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054367.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.